Teva Pharmaceutical Industries’ (TEVA) “Buy” Rating Reiterated at Maxim Group

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by equities researchers at Maxim Group in a research report issued to clients and investors on Friday. They currently have a $72.00 price target on the stock. Maxim Group’s target price points to a potential upside of 62.60% from the stock’s current price.

Other analysts have also issued reports about the stock. Goldman Sachs Group Inc. lowered their target price on shares of Teva Pharmaceutical Industries from $70.00 to $60.00 in a research note on Sunday, July 17th. HSBC raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Monday, July 18th. Mizuho reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Sunday, July 17th. Jefferies Group lowered their target price on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. Finally, Royal Bank Of Canada reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, July 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $67.06.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 44.28 on Friday. Teva Pharmaceutical Industries has a 52 week low of $43.80 and a 52 week high of $66.55. The stock has a 50 day moving average of $49.11 and a 200-day moving average of $52.25. The stock has a market cap of $40.47 billion, a PE ratio of 29.58 and a beta of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.05. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.86 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.43 earnings per share. Equities research analysts predict that Teva Pharmaceutical Industries will post $5.24 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board raised its stake in Teva Pharmaceutical Industries by 69.8% in the first quarter. Canada Pension Plan Investment Board now owns 1,075,410 shares of the company’s stock valued at $57,545,000 after buying an additional 442,200 shares in the last quarter. Lazard Asset Management LLC raised its stake in Teva Pharmaceutical Industries by 1.9% in the first quarter. Lazard Asset Management LLC now owns 12,949,435 shares of the company’s stock valued at $692,923,000 after buying an additional 240,228 shares in the last quarter. Edmond DE Rothschild Holding S.A. raised its stake in Teva Pharmaceutical Industries by 31.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 8,668 shares of the company’s stock valued at $467,000 after buying an additional 2,090 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Teva Pharmaceutical Industries by 26.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,015,673 shares of the company’s stock valued at $161,368,000 after buying an additional 624,629 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at approximately $2,428,000. Institutional investors and hedge funds own 63.35% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom


 
© 2006-2016 Ticker Report. Google+.